Ternary Therapeutics raises a £3.6m seed round led by daphni to engineer molecular glue medicines

Ternary Therapeutics develops computational and laboratory tools to design molecular glue medicines. Its platform predicts how proteins interact and suggests molecules that can bring them together, helping researchers target disease-driving proteins previously considered undruggable.